StockNews.com Begins Coverage on Trevena (NASDAQ:TRVN)

Equities researchers at StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN) in a note issued to investors on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and issued a $5.00 price objective on shares of Trevena in a research report on Thursday, November 14th.

Trevena Stock Up 0.6 %

TRVN opened at $1.67 on Friday. Trevena has a 12 month low of $1.13 and a 12 month high of $17.50. The company has a fifty day simple moving average of $1.73 and a 200 day simple moving average of $2.57. The stock has a market cap of $1.44 million, a P/E ratio of -0.04 and a beta of 1.08.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.